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Background: Our informal observations suggested that some patients with acute sensorineural hearing loss
(ASNHL) have subnormal serum immunoglobulin (Ig) levels. We evaluated 28 consecutive adults (18 men, 10
women) at ASNHL diagnosis using: antibodies to 68 kD protein, 30 kD protein, and type II collagen; and serum total
IgG, IgG subclasses, total IgA, and IgM. Reference ranges for Ig levels were mean ± 2 SD. We compared prevalences
of subnormal IgG subclasses to those in 275 healthy European adults in previous reports. We also reviewed charts
of consecutive adult index patients with primary Ig deficiency (35 common variable immunodeficiency, 406 IgG
subclass deficiency) to identify other patients with probable ASHNL.
Results: Mean age was 53 ± 10 (SD) y. Six patients (21.4%) had other autoimmunity manifestations. Antibodies to
68 kD protein, 30 kD protein, and type II collagen were detected in 21.4% (6/28), 21.1% (4/19) and 18.8% (3/16),
respectively. Three patients (10.7%) had subnormal IgG1, six (21.4%) had subnormal IgG3, and four (14.3%) had
subnormal IgG1 and IgG3. Some had subnormal IgG2, IgG4, IgA, and IgM (n = 1, 2, 3, and 1, respectively).
Prevalences of subnormal IgG1 or IgG3 were greater in ASNHL patients (25.0% and 35.7%) than 275 controls (2.1%
and 3.3%), respectively (p < 0.0001, each comparison). Relative risks of subnormal IgG1 and IgG3 in ASNHL were
11.5 [95% CI: 4.1, 31.7] and 10.9 [4.8, 25.6], respectively. Hearing improved after initial therapy in 17 patients (60.7%).
Multiple regressions on Ig levels revealed no significant associations with other available variables. Logistic
regressions on initial therapy response revealed a positive association with men (p = 0.0392) and a negative
association with IgA (p = 0.0274). Our estimated prevalence of probable ASNHL in 35 patients with common
variable immunodeficiency during a follow-up interval of 8 ± 4 y was 0% [95% CI: 0, 12.3]). Prevalence of probable
ASNHL in 406 patients with IgG subclass deficiency during the same interval was 0.74% [0.19, 2.33].
Conclusions: Serum levels of IgG1 or IgG3 were subnormal in 46.4% of 28 patients with ASNHL. Among adults
who present with primary Ig deficiency, some may have or later develop ASNHL.
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Autoimmune sensorineural hearing loss (ASNHL), also
called autoimmune inner ear disease or autoimmune hear-
ing loss, is characterized by rapidly progressive sensori-
neural hearing loss not explained by other defined causes
[1-3]. Inner ear antigens that have been proposed as targets
of putative deleterious autoantibodies in ASNHL include,
but are not limited to, 68 kD protein (often called heat-
shock protein) [4-6], 30 kD protein (often called myelin
Protein 0 or P0) [7,8], type II collagen [9], choline
transporter-like protein 2 [10-12], cochlin [13], and inner
ear supporting cell antigen [14]. Many patients with
ASNHL experience rapid improvement of hearing with
initial immunosuppressive therapy such as corticoste-
roids (systemic or intratympanic) [15], methotrexate
[16], or cyclophosphamide [1]. Analysis of a large med-
ical and pharmaceutical claims database indicated that
the incidence of sudden sensorineural hearing loss in
the U.S. is 27 per 100,000 per year [17].
In persons with diverse autoimmune disorders, the
prevalence of immunoglobulin (Ig) phenotypes typical of
common variable immunodeficiency (CVID) or IgG
subclass deficiency (IgGSD) is increased [18-20]. Thus, we
reviewed charts of 28 consecutive white adults referred to
a single practice for immunologic evaluation at diagnosis
of ASNHL. We measured serum levels of total IgG, IgG
subclasses, IgA, and IgM at diagnosis and estimated the
prevalence of subnormal Ig values in this cohort. We also
estimated the prevalence of ASNHL in 441 adult white
index patients with CVID/IgGSD who presented with
increased susceptibility to upper and lower respiratory tract
infections. We discuss the pertinence of our findings to the
evaluation, management, and pathogenesis of autoimmune
hearing loss.
We compared the prevalences of subnormal IgG sub-
class levels in the present 28 patients with ASNHL with
those in 275 healthy adults in three previous reports
[21-23]. We selected these reports because: a) abnormal
IgG subclass levels were defined as values more than 2 SD
from the mean, as in the present study; b) distinguishing
subjects with single subclass deficiency from those with
deficiency of two or more subclasses was possible; and c)
numbers of control subjects were at least as great in the
present ASNHL cohort [21-23]. We also estimated the




The performance of this work was approved by the
Institutional Review Board of Brookwood Medical Center.
Written informed consent of study subjects was not required
because the present report is based solely on retrieval and
analysis of observations made as part of routine medicalcare delivery and does not include personal identifier in-
formation. All patients were white adults referred to a sin-
gle hematology and medical oncology practice. We
evaluated two groups of patients. The first cohort com-
prised 28 consecutive unrelated patients referred by a sin-
gle otolaryngology practice during the interval 1998–2014
for immunological assessment at diagnosis of ASNHL,
including quantification of serum Ig levels. The second
cohort, 441 unrelated patients, were referred during the
interval 1998–2012 for evaluation and management of
hypogammaglobulinemia associated with increased
frequency or severity of upper or lower respiratory tract
infections poorly controlled by antibiotic therapy and
diagnosed to have CVID (n = 35) or IgGSD (n = 406).
All patients resided in Alabama.
Definition of ASNHL
ASNHL is defined herein as rapidly progressive bilateral
sensorineural hearing loss not explained by other defined
causes [1-3]. Inclusion or exclusion in this ASNHL case
series was not based on the presence or absence of anti-
bodies reactive with 68 kD protein, 30 kD protein, or type
II collagen or on response to initial immunosuppressive
therapy. The description of ASNHL patients is provided
with regard to unilateral/bilateral hearing loss and the
audiometric findings. Specifically, the Gardner-Robertson
Hearing Scale is utilized and referenced for both the better
and worse hearing ear.
Definition of CVID and IgGSD
We defined probable CVID in accordance with the criteria
of the Pan-American Group for Immunodeficiency and
the European Society for Immunodeficiency [24]. In
adults, these criteria include either men or women with
decreased levels of serum IgG and IgA at least 2 SD below
the mean; absent isohemagglutinins or poor response to
vaccines; and exclusion of other defined causes of hypo-
gammaglobulinemia [24]. IgGSD was defined as deficiency
of one or more IgG subclasses (IgG1-3) at least 2 SD
below the mean in the presence of normal total serum
IgG levels, with or without IgA deficiency [25].
Each patient diagnosed to have CVID or IgGSD was
tested for IgG levels specific for polysaccharide antigens of
one or more common serotypes of Streptococcus pneumo-
niae. We designated the first persons in respective families
diagnosed to have CVID/IgGSD as index patients. We
performed a manual review of medical charts and a com-
puterized review of electronic billing records to identify
CVID/IgSD index patients who also had histories or man-
ifestations suggesting that they had ASNHL.
Patient exclusions
ASNHL cohort. Patients with defined causes of hearing
loss other than ASNHL were excluded by history, initial
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malities of immunologic and other assessments. We ex-
cluded patients with clinical characteristics of Ménière
disease or immunologic abnormalities typical of Wegener
granulomatosis.
CVID/IgGSD cohort. We excluded patients from this co-
hort who were referred primarily for hearing loss evalu-
ation. We excluded subjects with isolated deficiencies of
IgA or IgM, normal immunoglobulin levels with deficiency
of selective IgG specificity for Streptococcus pneumoniae
polysaccharide antigen(s) serotypes; or hypogammaglobuli-
nemia attributed to B-cell neoplasms, organ transplantation,
immunosuppressive therapy, or increased immunoglobulin
loss. We excluded patients with either monoclonal gammo-
pathy of uncertain etiology, polyspecific gammopathy, or
diagnosis of HIV infection.
We excluded patients of African American descent be-
cause: a) mean serum concentrations of immunoglobulins
are often greater in adults of sub-Saharan African descent
than in white adults [26,27]; and b) persons of sub-Saharan
descent occur infrequently in series of CVID or IgGSD
patients [28]. During the study interval in which we diag-
nosed 441 white patients with CVID/IgGSD, we also evalu-
ated and diagnosed two African Americans who met the
same diagnostic criteria. Thus, only 2/443 CVID/IgGSD
patients were African American (0.0045 [95% CI: 0.0001,
0.0174]; Wald method).Laboratory methods
Assessments of anti-nuclear antibody (ANA), rheuma-
toid factor, cytoplasmic anti-neutrophil cytoplasmic
antibodies (c-ANCA), perinuclear anti-neutrophil cyto-
plasmic antibodies (p-ANCA), anti-cardiolipin anti-
bodies (IgG, IgA, and IgM specificities), and serum
protein immunoelectrophoreses (SIEP) were performed
using routine methods. Testing for serum levels of
anti-68 kD protein, anti-30 kD protein, and anti-type II
collagen antibodies was performed by IMMCO Diag-
nostics, Inc. (Buffalo, NY). Positivity for type II collagen
antibody was defined as >25 EU/mL.
Serum Ig levels were measured at diagnosis in patients
with ASNHL or before initiation of IgG replacement ther-
apy in patients diagnosed to have CVID/IgGSD. Serum
concentrations of total IgG, IgG subclasses, IgA, and IgM
were measured using standard automated methods. We
defined mean ± 2 SD as the normal or reference range for
all Ig measurements [18,21-23]. Reference ranges for
serum immunoglobulin concentrations are: total IgG 7.00-
16.00 g/L; IgG1 4.22-12.92 g/L; IgG2 1.17-7.47 g/L; IgG3
0.41-12.9 g/L; IgG4 0.01-2.91 g/L; total IgA 910–4140 mg/
L; and IgM 400–2300 mg/L. Subnormal serum Ig levels
were defined as concentrations below the corresponding
lower reference limit.Statistics
We performed initial logistic regressions on response to
initial immunosuppressive therapy (dichotomous variable)
in patients with ASNHL using these independent vari-
ables: age; sex; serum levels of IgG subclasses, IgA, and
IgM; and positivity for anti-68 kD protein, anti-30 kD pro-
tein, and anti-type II collagen antibodies (as dichotomous
variables). We excluded variables with values of p >0.1500
in initial regressions from the final regression models.
Analyses were performed with Excel 2000® (Microsoft
Corp., Redmond, WA) and GB-Stat® (v. 10.0, 2003, Dy-
namic Microsystems, Inc., Silver Spring, MD). Descrip-
tive data are displayed as enumerations, percentages, or
mean ± 1 standard deviation (SD). Prevalence or fre-
quency values were compared using chi-square analysis
or Fisher exact test (one-tail), as appropriate. We used
the Wald method to compute confidence intervals of pro-
portions. Prevalence estimates computed with continuity
corrections are expressed as percentage [95% confidence
interval, CI]. We computed relative risks (RR) by compar-
ing the present data with appropriate control observa-
tions. Multiple or logistic regressions were performed on
some independent variables, as appropriate, to identify
their associations with other variables. A value of p <0.05
was defined as significant.
Results
General characteristics
There were 28 patients (18 men; 10 women). Mean age at
diagnosis was 53 ± 10 y. Results of pre-treatment hearing
tests were available for review in 25 of the 28 patients
(89.3%). All 25 patients had bilateral asymmetric sensori-
neural hearing loss. According to the Gardner-Robertson
Hearing Scale [29], the better hearing ear for each patient
was classified as Grade I (Good) in 15 patients (60%),
Grade II (Serviceable) in 7 patients (28%), Grade III (Non-
serviceable) in 3 patients (12%), and Grade IV (Poor) and
Grade V (Deaf) in no patients. The worse hearing ear for
each patient was classified as Grade I in 1 patient (4%),
Grade II in 9 patients (36%), Grade III in 11 patients
(44%), Grade IV in no patients, and Grade V in 4 patients
(16%). An accurate determination of duration of symp-
toms was not available for most patients. No patient had
features of or was diagnosed to have Cogan syndrome.
Autoimmune manifestations
We tabulated reports of autoimmune manifestations in
each patient. One patient each had a history of “acute”
rheumatoid arthritis, seronegative rheumatoid arthritis,
Reiter’s syndrome, ulcerative colitis, and elevated ANA
(titer 1:320), respectively (6/28; 21.4%). There was chronic
activity of seronegative rheumatoid arthritis in one man,
intermittent activity of uveitis due to Reiter’s syndrome in
another man, and intermittent activity of ulcerative colitis
Bertoli et al. BMC Immunology 2014, 15:43 Page 4 of 8
http://www.biomedcentral.com/1471-2172/15/43in a woman. Three of ten women (33.3%) had hypo-
thyroidism (etiology not specified). Another woman
(10.0%)hadhypopituitarism.
Positivity for putative inner ear autoantibodies
Each of the present 28 patients (100%) was tested for posi-
tivity for anti-68 kD protein. Some patients were also
tested for other antibody specificities. Eight patients were
tested for a single antibody specificity; two of them
(25.0%) had a positive antibody test result. Five patients
were tested for two antibody specificities; three of them
(60.0%) were positive for a single antibody specificity.
Fifteen patients were tested for all three specificities. Five
of the 15 patients were positive for a single antibody speci-
ficity (33.3%) and the sixth patient was positive for all
three specificities. A Pearson’s chi-square test revealed
that these proportions across the three antibody specific-
ities tested did not differ significantly (p = 0.4522).
Anti-68 kD protein antibody was detected in 6 of 28 pa-
tients (21.4%; [95% CI: 9.0, 41.5]). Anti-30 kD protein anti-
body was detected in 4 of 19 patients (21.1%; [7.0, 46.1]).
Anti-type II collagen antibody was detected in 3 of 16
patients (18.8%; [5.0, 46.3]).
Miscellaneous test results
The initial assessment in each patient included complete
blood count, ANA, rheumatoid factor, anti-leukocyte anti-
bodies (c-ANCA; p-ANCA), and anti-cardiolipin anti-
bodies. Some patients underwent testing for syphilis or
human immunodeficiency virus-1 infection, hematologic
malignancy, heritable disorders, or abnormalities detectable
on magnetic resonance imaging, as appropriate. No patient
had significant abnormalities detected by these tests (results
not shown). SIEP did not reveal a monoclonal immuno-
globulin in any patient.
Serum Ig levels
At diagnosis, mean Ig levels (range) in 28 patients were:
total IgG 8.67 ± 2.20 g/L [95% CI: 7.82, 9.52]; IgG1 5.01
± 1.62 g/L [4.36, 5.64]; IgG2 2.87 ± 1.11 g/L [2.43, 3.31];
IgG3 0.53 ± 0.28 g/L [0.42, 0.64]; and IgG4 0.25 ± 0.19 g/
L [0.17, 0.32]. Mean total IgA level was 1790 ± 730 mg/L
[1500, 2070]. Mean IgM level was 1230 ± 930 mg/L [870,
1590]. Subnormal serum levels of total IgG were de-
tected in five patients (17.9%). Three patients (10.7%)
had subnormal IgG1, six (21.4%) had subnormal IgG3,
and four (14.3%) had subnormal IgG1 and IgG3. Subnor-
mal serum levels of either IgG1 or IgG3 were observed
in nine men (50.0%) and four women (40.0%). Two
patients had subnormal serum levels of IgG4: one of the
two patients had a subnormal serum level of IgG1 and the
other patient had subnormal serum levels of IgG1, IgG2,
and IgG3. Altogether, 13 patients (46.4%) had subnormal
serum levels of one or more IgG subclass (es).Three of six patients (50.0%) who were positive for anti-
68 kD protein antibody also had subnormal serum levels of
IgG1 or IgG3. Ten of 22 patients (45.5%) who were nega-
tive for anti-68 kD protein antibody had subnormal serum
levels of IgG1 or IgG3. The difference between these pro-
portions was not significant (50.0% vs. 45.5%; p = 0.6005).
Subnormal serum levels of total IgA were observed in
three patients (740, 750, and 780 mg/L, respectively). One
patient had a subnormal serum level of IgM (150 mg/L).
Mild elevation of serum levels of IgM were observed in
four patients (2510, 2580, 2850, and 4090 mg/L, respect-
ively). No patient had an increased serum level of total
IgG, a IgG subclass, or total IgA. No patient had evidence
of a monoclonal protein by SIEP criteria.
Prevalence and RR of subnormal Ig levels in ASNHL
patients and controls
We combined previous observations on IgG subclass
levels in three groups of healthy subjects previously re-
ported (125 Irish blood donors; 68 German blood donors;
82 English women) to a create an aggregate group of 275
controls [21-23] (Table 1). The prevalences of subnormal
serum IgG1 and IgG3 levels in 28 patients with ASNHL
were significantly higher than corresponding levels in the
275 control subjects (Table 1). The proportions of normal
controls who had subnormal IgG1 and IgG3 levels (2.1%
and 3.3%, respectively) are consistent with the 2.5% of
values predicted to occur below 2 SD from the mean
(Table 1). The prevalence of subnormal serum IgG2 and
IgG4 levels in 28 patients with ASNHL did not differ
significantly from those in 275 control subjects (Table 1).
Regressions on serum Ig levels
We performed a regression on serum IgG1 levels using
these independent variables: age; sex; serum levels of IgG2,
IgG3, IgG4, total IgA, and IgM; positivity for antibodies re-
active with 68 kD protein, 30 kD protein, and type II colla-
gen; and history of autoimmune manifestations. This
revealed no significant associations. Corresponding regres-
sions on serum total IgG, IgG2, IgG3, IgG4, IgA, and IgM
levels also revealed no significant associations.
Response to initial therapy of ASNHL
Initial therapy was oral corticosteroids (n = 23), intratympa-
nic corticosteroid infusion (n = 3), oral methotrexate (n = 1),
and oral cyclophosphamide (n = 1). Hearing improved sig-
nificantly with initial therapy in 17 patients (60.7%; [95% CI:
40.7, 77.9]).
Response to initial therapy was observed in 14 men
(77.8%) and three women (33.3%) (p = 0.0189). The mean
ages of responders and non-responders were 53 ± 12 y
and 53 ± 8 y, respectively (p = 0.9940). Four of 6 patients
positive for anti-68 kD protein antibody (66.7%) and 13 of
22 patients negative for anti-68 kD protein antibody
Table 1 Subnormal serum IgG subclass levels in adultsa
Cohort Subnormal Ig level (n)b Prevalence [95% CI]; value of pc Relative risk [95% CI]; value of pc
28 ASNHL patients IgG1 (7) 25.0 [11.4, 45.2]; <0.0001 11.5 [4.1, 31.7]; <0.0001
IgG2 (1) 3.6 [0.2, 20.2]; 0.3863 2.5 [0.3, 21.2]; 0.4143
IgG3 (8) 35.7 [9.3, 55.9]; <0.0001 8.7 [3.7, 20.8]; <0.0001
IgG4 (2) 7.1 [1.3, 25.0]; 0.1978 3.0 [0.7, 13.8]; 0.1561
275 healthy controls IgG1 (6) 2.1 [0.9, 4.9] -
IgG2 (4) 1.5 [0.5, 3.9] -
IgG3 (9) 3.3 [1.6, 6.3] -
IgG4 (7) 2.6 [1.1, 5.4] -
aReference ranges for serum IgG subclass levels were mean ± 2 SD for age. Controls included: 125 healthy Irish adult blood donors (68 men, 57 women; ages 48 ±
16 (range 22–81 y); 82 healthy English women (mean 57 y; range 22–90 y); and 68 healthy German blood donors (36 men, 32 women; ages 20–61 years) [21-23].
bSubnormal serum IgG subclass levels were reported in these control subjects: IgG1 (3 Ireland, 2 England, 1 Germany); IgG2 (2 Ireland, 2 Germany); IgG3 (3 Ireland,
6 Germany); and IgG4 (4 Ireland, 1 England, and 2 Germany) [21-23].
cComparisons with 275 controls [21-23].
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values of serum Ig levels did not differ significantly between
responders and non-responders (data not shown).
We performed logistic regression on response to initial
therapy using these independent variables: age; sex; serum
levels of IgG1, IgG2, IgG3, IgG4, total IgA, and IgM; posi-
tivity for antibodies reactive with 68 kD protein, 30 kD
protein, and type II collagen; and history of autoimmune
manifestations. In an initial regression model, age, sex,
and serum levels of total IgA and IgM were possible pre-
dictors of response to initial therapy (values of p ≤0.1500).
In a refined model using only these four independent vari-
ables, there was a positive association of response to ther-
apy in men (p = 0.0392) and a negative association with
serum total IgA levels (p = 0.0274). This accounted for
34.6% of the model variance in the predictors of the
dichotomous response variable.
Respiratory tract infections in 28 ASNHL patients
One woman with subnormal IgG3 levels reported having
increased frequency or severity of upper and lower respira-
tory tract infections at diagnosis of ASNHL. Her treatment
included monthly IgG replacement. One man with subnor-
mal IgG3 levels reported having recurrent upper and lower
respiratory tract infections ~18 months after diagnosis of
ASNHL and was subsequently treated with monthly IgG
replacement.
Prevalence of probable ASNHL in 441 patients with CVID/
IgGSD
Among 406 IgGSD index patients, retrospective review of
medical charts revealed evidence of ASNHL in three
patients. One woman presented at age 52 years with acute
bilateral hearing loss responsive to intravenous corticoster-
oid therapy, systemic lupus erythematosus with cerebritis,
Sjögren syndrome, and subnormal serum levels of IgG3,
although she was not evaluated in our clinic for these
complaints. Six months later, she was referred to our clinicbecause she had recurrent upper and lower respiratory
tract infections. She was subsequently treated with
monthly IgG replacement. A 61 year-old woman with
subnormal levels of IgG1 and IgG3 reported having “ster-
oid-responsive hearing loss.” A 45 year-old man with sub-
normal levels of IgG1 and IgG3 was reported to have
“idiopathic hearing loss responding to prednisone within
three months.” Considering these patients to have probable
ASNHL, our estimated prevalence of ASNHL in 406
patients with IgGSD during a mean follow-up interval of
8 ± 4 y was 0.74% [95% CI: 0.19, 2.33]. We found no
reports of ASNHL in 35 index patients with CVID during
the same follow-up interval (0%; [0, 12.3]).
Discussion
A novel finding of the present study is that subnormal
IgG1 and IgG3 levels are common in white adults with
ASNHL. The prevalence and RR of subnormal IgG1 and
IgG3 levels were significantly higher in the present pa-
tients than in 275 healthy adults in three previous reports
[21-23]. Some patients with ASNHL had at diagnosis or
eventually developed frequent or severe upper or lower re-
spiratory tract infections. In index patients with CVID and
IgGSD, selective or combined deficiencies of IgG1 and
IgG3 and diverse autoimmune disorders are common
[18-20]. In our retrospective review of the records of 441
index patients with CVID/IgGSD, we identified three
other patients with probable ASNHL. Each of them had
subnormal serum levels of IgG1 or IgG3, typical of other
index patients with CVID/IgGSD phenotypes in this geo-
graphic area [18,30].
Our observations did not suggest a consistent chrono-
logic relationship between reports of upper and lower
respiratory tract infections and the onset of ASNHL. One
of the present 28 patients presented simultaneously with
the two conditions. Another patient began to experi-
ence recurrent upper and lower respiratory tract infec-
tions ~18 months after diagnosis of ASNHL. Among
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possible ASNHL. One of them began having frequent
respiratory tract infections six months after diagnosis of
ASNHL. A temporal relationship between respiratory
tract infections and possible ASNHL in the other two
IgGSD patients could not be ascertained from available
records.
There was a predominance of men in the present
ASNHL cohort. Estimates from a large medical and
pharmaceutical claims database revealed a slight male pre-
ponderance (male-to-female ratio 1.07:1) among persons
with sudden sensorineural hearing loss. In patients 65 years
of age or older, the ratio was 1.30:1 [17]. The mean age of
the present 28 patients is similar to that in other ASNHL
case series [2]. We observed evidence of autoimmune man-
ifestations other than ASNHL in 21% of the present cohort,
consistent with previous reports of autoimmune disorders
in other persons with ASNHL [1,31,32]. Hearing improved
with initial therapy in 64% of the present patients. The re-
sponse rate to initial therapy with oral prednisolone treat-
ment was 70% in 47 other patients with ASNHL [3]. Taken
together, general characteristics of the 28 present patients
are similar to those of patients in other ASNHL case series.
Subnormal levels of IgG1 and IgG3 in many patients
with CVID or IgGSD are transmitted as dominant traits
linked to human leukocyte antigen (HLA)-A and -B
types and haplotypes encoded in the major histocom-
patibility complex on chromosome 6p [18,30]. Some
HLA class II and I markers have also been associated
with ASNHL [33-35]. IgG3 is the most polymorphic
human IgG subclass and includes thirteen G3m allotypes
(variants of Ig heavy G chains) which constitute six
major G3m alleles of IGHG3 on chromosome 14q32.33
[36]. Allotypes are characterized by differences in amino
acid epitopes of the constant heavy G chains and are
inherited in a Mendelian manner [36-39]. Thus, alleles
that increase risk for ASNHL may be linked to genetic
determinants of serum IgG1 and IgG3 levels on chromo-
some 6p or chromosome 14q32.33 in some patients.
Positivity for anti-68 kD protein antibody is associated
with the diagnosis of autoimmune hearing loss [3,4,6,40],
although no single antibody-related test result presently
known establishes or excludes ASNHL diagnosis. In the
present study, the percentages of the patients who had
subnormal serum levels of IgG1 or IgG3 did not differ sig-
nificantly between those with and those without anti-68
kD protein antibody.
Using logistic regression, we detected a positive associ-
ation of response to initial therapy in men and a negative
association of response to initial therapy with serum total
IgA levels. In another ASNHL case series, univariable
methods revealed that positivity for anti-68 kD protein anti-
body was a fair predictor of response to initial therapy [23].
In another report, antibody to an inner ear supporting cellantigen was significantly associated with hearing improve-
ment after corticosteroid therapy [14]. Antibodies to recom-
binant choline transporter-like protein 2 were associated
with responses to initial therapy in some patients [11]. Bio-
logical heterogeneity in putative target inner ear antigens
and their corresponding autoantibodies across patients with
ASNHL could partly explain these observations.
We observed subnormal serum levels of IgG1 or IgG3 in
46% of the present patients, although few of them reported
having increased frequency or severity of respiratory tract
infections at diagnosis of ASNHL. Consequently, we did
not routinely quantify serum IgG specificities to capsular
polysaccharides of common serotypes of Streptococcus
pneumoniae or measure specific IgG responses to vaccin-
ation with polyvalent pneumococcal antigens or tetanus
toxoid. Two of the 28 present patients developed increased
frequency or severity of respiratory tract infections at the
time of or after ASNHL diagnosis. Among 441 CVID/
IgGSD patients, three probably had ASNHL. These obser-
vations suggest that evaluating patients with ASNHL by
taking histories of infections and measuring serum Ig levels
may reveal infection-related manifestations or subnormal
serum levels of IgG subclasses, especially IgG1 and IgG3.
Uncertainties of the present work include the possibility
that greater numbers of patients may have permitted elu-
cidation of other relationships of available variables with
subnormal serum levels of IgG1 or IgG3 or response to
initial therapy. We did not determine whether initial oral
or intratympanic corticosteroids or oral methotrexate or
cyclophosphamide administered to alleviate hearing loss
significantly affected serum Ig levels in the present
patients. It is possible that other patients in the present
cohort now lost to follow-up have developed either sub-
normal Ig levels or increased susceptibility to respiratory
tract infections not present at ASNHL diagnosis. Evaluat-
ing serum Ig levels in patients with sudden hearing loss or
Ménière syndrome would permit additional comparisons
and contrasts among persons with hearing loss syndromes,
but such evaluation was beyond the scope of the present
work. Performing HLA typing or Gm allotyping or geno-
typing was beyond the scope of the present work.Conclusions
Serum levels of IgG1 or IgG3 were subnormal in 46.4% of
28 patients with ASNHL. Among adults who present with
primary Ig deficiency, some may have or later develop
ASNHL.
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